Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4533966 | 0.86 | EPHX2 (0.46) | EPHX2PDE2ASLC7A5HCRTR1HCRTR2 | |
| SCHEMBL9060560 | 0.84 | CYP17A1 (0.46) | CYP17A1EPHX2CTSKNAAAKIF11 | |
| SCHEMBL12199925 | 0.84 | CYP17A1 (0.46) | CYP17A1EPHX2CTSKNAAAKIF11 | |
| SCHEMBL7782198 | 0.83 | EPHX2 (0.46) | CYP17A1EPHX2CTSKNAAAKIF11 | |
| SCHEMBL9062079 | 0.81 | CYP17A1 (0.43) | CYP17A1EPHX2CTSKNAAAKIF11 | |
| SCHEMBL10078774 | 0.81 | CYP17A1 (0.47) | CYP17A1EPHX2CTSKNAAAKIF11 | |
| SCHEMBL9061797 | 0.79 | RARB (0.49) | CYP17A1EPHX2CTSKNAAAKIF11 | |
| SCHEMBL15545618 | 0.78 | KIF11 (0.56) | EPHX2CTSKNAAAKIF11PDE2A | |
| SCHEMBL12889521 | 0.78 | PDE2A (0.45) | CYP17A1EPHX2CTSKNAAAKIF11 | |
| SCHEMBL508418 | 0.78 | NAAA (0.39) | EPHX2CTSKNAAAPDE2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2459571-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | Global Alliance For Tb Drug Development (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011014774-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | CYP17A1 3289/4885EPHX2 2277/4885CTSK 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.